NasdaqGS - Delayed Quote USD

Dyne Therapeutics, Inc. (DYN)

24.73 +1.03 (+4.37%)
At close: April 26 at 4:00 PM EDT
24.73 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
242,162.00
242,162.00
170,962.00
150,025.00
58,647.00
Operating Income
-242,162.00
-242,162.00
-170,962.00
-150,025.00
-58,647.00
Net Non Operating Interest Income Expense
7,641.00
7,641.00
2,917.00
742.00
-340.00
Other Income Expense
-1,416.00
-1,416.00
-54.00
-8.00
-450.00
Pretax Income
-235,937.00
-235,937.00
-168,099.00
-149,291.00
-59,437.00
Net Income Common Stockholders
-235,937.00
-235,937.00
-168,099.00
-149,291.00
-59,437.00
Diluted NI Available to Com Stockholders
-235,937.00
-235,937.00
-168,099.00
-149,291.00
-59,437.00
Basic EPS
-3.95
--
-3.23
-2.93
-4.13
Diluted EPS
-3.95
--
-3.23
-2.93
-4.13
Basic Average Shares
59,683.85
--
51,976.34
50,895.04
14,395.96
Diluted Average Shares
59,683.85
--
51,976.34
50,895.04
14,395.96
Total Operating Income as Reported
-242,162.00
-242,162.00
-170,962.00
-150,025.00
-58,647.00
Total Expenses
242,162.00
242,162.00
170,962.00
150,025.00
58,647.00
Net Income from Continuing & Discontinued Operation
-235,937.00
-235,937.00
-168,099.00
-149,291.00
-59,437.00
Normalized Income
-235,937.00
-235,937.00
-168,099.00
-149,291.00
-59,437.00
Interest Income
7,641.00
7,641.00
2,917.00
742.00
56.00
Interest Expense
--
--
--
--
396.00
Net Interest Income
7,641.00
7,641.00
2,917.00
742.00
-340.00
EBIT
-242,162.00
-242,162.00
-170,962.00
-150,025.00
-59,041.00
EBITDA
-240,489.00
-240,489.00
-169,279.00
-148,937.00
-58,341.00
Reconciled Depreciation
1,673.00
1,673.00
1,683.00
1,088.00
700.00
Net Income from Continuing Operation Net Minority Interest
-235,937.00
-235,937.00
-168,099.00
-149,291.00
-59,437.00
Normalized EBITDA
-240,489.00
-240,489.00
-169,279.00
-148,937.00
-58,341.00
12/31/2020 - 9/17/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RNA Avidity Biosciences, Inc.
24.36
+2.22%
 
MOR MorphoSys AG
18.04
-0.50%
 
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
 
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
 
MLTX MoonLake Immunotherapeutics
42.49
+0.57%
 
RVMD Revolution Medicines, Inc.
35.96
+1.78%
 
SWTX SpringWorks Therapeutics, Inc.
45.53
+3.01%
 
JANX Janux Therapeutics, Inc.
47.39
+0.62%
 
KROS Keros Therapeutics, Inc.
57.86
+6.77%
 
FDMT 4D Molecular Therapeutics, Inc.
23.25
-1.19%